322 related articles for article (PubMed ID: 20139798)
1. ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir.
Lubomirov R; di Iulio J; Fayet A; Colombo S; Martinez R; Marzolini C; Furrer H; Vernazza P; Calmy A; Cavassini M; Ledergerber B; Rentsch K; Descombes P; Buclin T; Decosterd LA; Csajka C; Telenti A;
Pharmacogenet Genomics; 2010 Apr; 20(4):217-30. PubMed ID: 20139798
[TBL] [Abstract][Full Text] [Related]
2. CYP3A5, ABCB1, and SLCO1B1 polymorphisms and pharmacokinetics and virologic outcome of lopinavir/ritonavir in HIV-infected children.
Rakhmanina NY; Neely MN; Van Schaik RH; Gordish-Dressman HA; Williams KD; Soldin SJ; van den Anker JN
Ther Drug Monit; 2011 Aug; 33(4):417-24. PubMed ID: 21743379
[TBL] [Abstract][Full Text] [Related]
3. Absence of circadian variation in the pharmacokinetics of lopinavir/ritonavir given as a once daily dosing regimen in HIV-1-infected patients.
van Heeswijk RP; Bourbeau M; Seguin I; Giguere P; Garber GE; Cameron DW
Br J Clin Pharmacol; 2005 Apr; 59(4):398-404. PubMed ID: 15801934
[TBL] [Abstract][Full Text] [Related]
4. Amprenavir and lopinavir pharmacokinetics following coadministration of amprenavir or fosamprenavir with lopinavir/ritonavir, with or without efavirenz.
Pham PA; Hendrix CW; Barditch-Crovo P; Parsons T; Khan W; Parish M; Radebaugh C; Carson KA; Pakes GE; Qaqish R; Flexner C
Antivir Ther; 2007; 12(6):963-9. PubMed ID: 17926651
[TBL] [Abstract][Full Text] [Related]
5. Coadministration of lopinavir/ritonavir and phenytoin results in two-way drug interaction through cytochrome P-450 induction.
Lim ML; Min SS; Eron JJ; Bertz RJ; Robinson M; Gaedigk A; Kashuba AD
J Acquir Immune Defic Syndr; 2004 Aug; 36(5):1034-40. PubMed ID: 15247556
[TBL] [Abstract][Full Text] [Related]
6. Differences in genetic variants in lopinavir disposition among HIV-infected Bantu Africans.
Mpeta B; Kampira E; Castel S; Mpye KL; Soko ND; Wiesner L; Smith P; Skelton M; Lacerda M; Dandara C
Pharmacogenomics; 2016 May; 17(7):679-90. PubMed ID: 27142945
[TBL] [Abstract][Full Text] [Related]
7. Electrocardiogram abnormalities with atazanavir and lopinavir/ritonavir.
Rathbun CR; Liedtke MD; Blevins SM; Harrison D; Lockhart SM; Salvaggio M; Acosta EP
HIV Clin Trials; 2009; 10(5):328-36. PubMed ID: 19906626
[TBL] [Abstract][Full Text] [Related]
8. Pharmacogenetic analysis of SNPs in genes involved in the pharmacokinetics and response to lopinavir/ritonavir therapy.
López Aspiroz E; Cabrera Figueroa SE; Porras Hurtado GL; Cruz Guerrero R; Domínguez-Gil Hurlé A; Carracedo A;
Curr Drug Metab; 2013 Sep; 14(7):729-37. PubMed ID: 24001122
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and tolerability of once- versus twice-daily lopinavir/ritonavir treatment in HIV-1-infected children.
la Porte C; van Heeswijk R; Mitchell CD; Zhang G; Parker J; Rongkavilit C
Antivir Ther; 2009; 14(4):603-6. PubMed ID: 19578247
[TBL] [Abstract][Full Text] [Related]
10. Simultaneous pharmacogenetics-based population pharmacokinetic analysis of darunavir and ritonavir in HIV-infected patients.
Moltó J; Xinarianos G; Miranda C; Pushpakom S; Cedeño S; Clotet B; Owen A; Valle M
Clin Pharmacokinet; 2013 Jul; 52(7):543-53. PubMed ID: 23494984
[TBL] [Abstract][Full Text] [Related]
11. The impact of SLCO1B1 polymorphisms on the plasma concentration of lopinavir and ritonavir in HIV-infected men.
Kohlrausch FB; de Cássia Estrela R; Barroso PF; Suarez-Kurtz G
Br J Clin Pharmacol; 2010 Jan; 69(1):95-8. PubMed ID: 20078617
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetics of lopinavir in combination with ritonavir in HIV-1-infected patients.
Crommentuyn KM; Kappelhoff BS; Mulder JW; Mairuhu AT; van Gorp EC; Meenhorst PL; Huitema AD; Beijnen JH
Br J Clin Pharmacol; 2005 Oct; 60(4):378-89. PubMed ID: 16187970
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenetics-based population pharmacokinetic analysis of etravirine in HIV-1 infected individuals.
Lubomirov R; Arab-Alameddine M; Rotger M; Fayet-Mello A; Martinez R; Guidi M; di Iulio J; Cavassini M; Günthard HF; Furrer H; Marzolini C; Bernasconi E; Calmy A; Buclin T; Decosterd LA; Csajka C; Telenti A;
Pharmacogenet Genomics; 2013 Jan; 23(1):9-18. PubMed ID: 23111422
[TBL] [Abstract][Full Text] [Related]
14. Effect of an antiretroviral regimen containing ritonavir boosted lopinavir on intestinal and hepatic CYP3A, CYP2D6 and P-glycoprotein in HIV-infected patients.
Wyen C; Fuhr U; Frank D; Aarnoutse RE; Klaassen T; Lazar A; Seeringer A; Doroshyenko O; Kirchheiner JC; Abdulrazik F; Schmeisser N; Lehmann C; Hein W; Schömig E; Burger DM; Fätkenheuer G; Jetter A
Clin Pharmacol Ther; 2008 Jul; 84(1):75-82. PubMed ID: 18183034
[TBL] [Abstract][Full Text] [Related]
15. Lopinavir exposure with an increased dose during pregnancy.
Mirochnick M; Best BM; Stek AM; Capparelli E; Hu C; Burchett SK; Holland DT; Smith E; Gaddipati S; Read JS;
J Acquir Immune Defic Syndr; 2008 Dec; 49(5):485-91. PubMed ID: 18989231
[TBL] [Abstract][Full Text] [Related]
16. The pharmacokinetics of lopinavir/ritonavir when given with isoniazid in South African HIV-infected individuals.
Decloedt EH; van der Walt JS; McIlleron H; Wiesner L; Maartens G
Int J Tuberc Lung Dis; 2015 Oct; 19(10):1194-6. PubMed ID: 26459532
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of two generic co-formulations of lopinavir/ritonavir for HIV-infected children: a pilot study of paediatric Lopimune versus the branded product in healthy adult volunteers.
de Kanter CT; Colbers EP; Fillekes Q; Hoitsma A; Burger DM
J Antimicrob Chemother; 2010 Mar; 65(3):538-42. PubMed ID: 20056686
[TBL] [Abstract][Full Text] [Related]
18. First line zidovudine/lamivudine/lopinavir/ritonavir leads to greater bone loss compared to nevirapine/lopinavir/ritonavir.
van Vonderen MG; Lips P; van Agtmael MA; Hassink EA; Brinkman K; Geerlings SE; Sutinen J; Ristola M; Danner SA; Reiss P
AIDS; 2009 Jul; 23(11):1367-76. PubMed ID: 19424051
[TBL] [Abstract][Full Text] [Related]
19. Association between ABCC2 polymorphism and lopinavir accumulation in peripheral blood mononuclear cells of HIV-infected patients.
Elens L; Yombi JC; Lison D; Wallemacq P; Vandercam B; Haufroid V
Pharmacogenomics; 2009 Oct; 10(10):1589-97. PubMed ID: 19842932
[TBL] [Abstract][Full Text] [Related]
20. Clinical impact of double protease inhibitor boosting with lopinavir/ritonavir and amprenavir as part of salvage antiretroviral therapy.
Loutfy M; Raboud J; Thompson C; Tseng A; Abdurrahman Z; Kovacs C; Rachlis A; Phillips E; Rubin G; Gough K; Walmsley S
HIV Clin Trials; 2003; 4(5):301-10. PubMed ID: 14583846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]